Buradasınız

Anasayfa » Content

Obez Kadın Hastalarda Plazma Homosistein Seviyeleri Homosistein ve Obezite

Levels of Plasma Homocysteine in Obese Women Subjects Homocysteine and Obesity

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2014
DOI: 
10.5262/tndt.2014.1002.03

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
OBJEC TIVE: An increased homocysteine level is an independent risk factor for vascular diseases. The present study was designed to evaluate plasma homocysteine levels in obese women compared with non-obese healthy women. MATERIAL and ME THODS: We selected 55 obese women (mean age 47.2±9.2 years) having a body mass index ≥ 30 kg/m² and 50 non-obese healthy women matched for age (mean age 46.3±9.5 years) who attended our outpatients clinic. We measured levels of homocysteine in obese and nonobese groups. RES ULTS: No significant difference was observed between obese and non-obese control groups regarding the homocysteine levels (10.3±3.5 μmol/l vs. 10.1±3.8 μmol/l , p>0.05). In this selected study population as a whole, the correlation between homocysteine levels and body mass index did not attain statistical significance (r=0.12, p>0.05). CONCL USION: We found that homocysteine levels were comparable between middle-aged obese and non-obese women. Our data may suggest that increased cardiovascular risk in obese women is probably not related to the homocysteine level.
Bookmark/Search this post with
Abstract (Original Language): 
AMAÇ: Artmış homosistein seviyesi vasküler hastalıklar için bağımsız bir risk faktörüdür. Bu çalışma, obez ve obez olmayan kadınlarda plazma homosistein düzeylerinin değerlendirilmesine yönelik tasarlanmıştır. GEREÇ ve YÖNTEMLE R: Çalışmaya polikliniğimize başvuran, vücut kitle indeksi ≥ 30 kg/m² olan 55 obez kadın (ortalama yaş 47,2±9,2 yıl) ve aynı yaş grubundan (ortalama yaş 46,3±9,5 yıl) 50 obez olmayan sağlıklı kadın seçtik. Obez ve obez olmayan gruplarda homosistein düzeylerini ölçtük. BULGULAR: Obez ve obez olmayan kontrol grubu arasında homosistein düzeyleri (10.3±3.5 μmol/l vs. 10,1±3,8 μmol/l , p>0,05) açısından anlamlı farklılık tespit edilmedi. Çalışmaya seçilmiş populasyonda, homosistein seviyeleri ile vücut kitle indeksi arasında istatistiksel olarak anlamlı korelasyon tespit edilmedi (r=0,12, p>0,05). SONUÇ: Orta yaş obez ve obez olmayan kadınlarda homosistein düzeylerinin benzer olduğunu saptadık. Verilerimiz obezitede artmış kardiyovasküler risk ile homosistein düzeyleri arasında ilişki olmadığına işaret edebilir.
FULL TEXT (PDF): 
PDF icon arastirmax-obez-kadin-hastalarda-plazma-homosistein-seviyeleri-homosistein-obezite.pdf
  • 2
91
94
  • Turkish

REFERENCES

References: 

1. Poirier P, Eckel RH: Obesity and cardiovascular disease. Curr
Atheroscler Rep 2002; 4: 448-453
2. Eckel RH, Krauss RM: American Heart Association call to action:
Obesity as a major risk factor for coronary heart disease. AHA
Nutrition Committee. Circulation 1998; 97: 2099-21003. Kumanyika S, Jeffery RW, Morabia A, Ritenbaugh C, Antipatis VJ:
Obesity prevention: The case for action. Int J Obes Relat Metab
Disord 2002; 26: 425-436
4. Bostom AG, Selhub J: Homocysteine and arteriosclerosis.
Subclinical and clinical disease associations. Circulation 1999; 99:
2361-2363
5. Scott JM: Homocysteine and cardiovascular risk. Am J Clin Nutr
2000; 72: 333-334
6. Haynes WG: Hyperhomocysteinemia, vascular function and
atherosclerosis: Effects of vitamins. Cardiovascular Drugs Ther
2002; 16: 391-399
7. Plazar N, Jurdana M: Hyperhomocysteinemia: Relation to
Cardiovascular Disease and Venous Thromboembolism. www.
intechopen.com/download/pdf/37048
8. Kalra DK: Homocysteine and Cardiovascular Disease. Curr
Atheroscler Rep 2004; 6: 101-106
9. Pierdomenico SD, Bucci A, Lapenna D, Lattanzio FM, Talone
L, Cuccurullo F, Mezzetti A: Circulating homocysteine levels in
sustained and white coat hypertension. J Hum Hypertens 2003; 17:
165-170
10. Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S:
Homocysteine and cardiovascular disease: A critical review of the
epidemiologic evidence. Ann Intern Med 1999; 131: 363-375
11. Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE,
Ueland PM, Palma-Reis RJ, Boers GH, Sheahan RG, Israelsson
B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman
J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales Lúis AC,
Parrot-Rouland FM, Tan KS, Higgins I, Garcon D, Andria G:
Plasma homocysteine as a risk factor for vascular disease. The
European Concerted Action Project. JAMA 1997; 277: 1775-1781
12. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M,
Vollset SE: Plasma homocysteine levels and mortality in patients
with coronary arter disease. N Engl J Med 1997: 337: 230-236
13. Friedewald WT, Levi RI, Fredricksen DS: Estimation of the
concentration of low-density lipoprotein cholesterol in plasma,
without use of the preparative ultracentrifuge. Clin Chem 1972; 18:
499-502
14. Marchesini S, Manini R, Bianchi G, Sassi S, Natale S, Chierici S,
Visani F, Baraldi L, Forlani G, Melchionda N: Homocysteine and
psychological traits: A study in obesity. Nutrition 2002; 18: 403-407
15. Tungtrongchitr R, Pongpaew P, Tongboonchoo C, Vudhivai N,
Changbumrung S, Tungtrongchitr A, Phonrat B, Viroonudomphol
D, Pooudong S, Schelp FP: Serum homocysteine, B12 and folic
acid concentration in Thai overweight and obese subjects. Int J
Vitam Nutr Res 2003; 73: 8-1416. Konukoglu D, Serin O, Turhan MS: Plasma total homocysteine
concentrations in obese and non-obese female patients with type
2 diabetes mellitus; its relations with plasma oxidative stress and
nitric oxide levels. Clin Hemorheol Microcirc 2005; 33: 41-46
17. Akoglu B, Wondra K, Casparu WF, Faust D: Determinants of fasting
total serum homocysteine levels in liver transplant recipients. Exp
Clin Transplant 2006; 4: 462-466
18. Jacques PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, Selhub
J: Determinants of plasma total homocysteine concentration in the
Framingham Offspring cohort. Am J Clin Nutr 2001; 73: 613-621
19. Koehler KM, Romero LJ, Stauber PM, Pareo-Tubbeh SL, Liang
HC, Baumgartner RN, Garry PJ, Allen RH, Stabler SP: Vitamin
supplementation and other variables affecting serum homocysteine
and methylmalonic acid concentrations in elderly men and women.
J Am Coll Nutr 1996;15: 364-376
20. Lussier-Cacan S, Xhignesse M, Piolot A, Selhub J, Davignon J,
Genest J Jr: Plasma total homocysteine in healthy subjects: Sexspecific
relation with biological traits. Am J Clin Nutr 1996; 64:
587-593
21. Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A,
Nordrehaug JE, Ueland M, Kvåle G: Total plasma homocysteine
and cardiovascular risk profile. The Hordaland Homocysteine
Study. JAMA 1995; 274: 1526-1533
22. Uysal O, Arikan E, Cakir B: Plasma total homocysteine level and
its association with carotid intima-media thickness in obesity. J
Endocrinol Invest 2005; 28: 928-934
23. Brasilerio RS, Escrivão MA, Taddei JA, D’Almeida V, Ancona-
Lopez F, Carvalhaes JT: Plasma total homocysteine in Brazilian
overweight and non-overweight adolescents: A case-control study.
Nutr Hosp 2005; 20: 313-319
24. Fonseca VA, Fink LM, Kern PA: Insulin sensitivity and plasma
homocysteine concentrations in non-diabetic obese and normal
weight subjects. Atherosclerosis 2003; 167: 105-109
25. Pi-Sunyer FX: A review of long-term studies evaluating the efficacy
of weight loss in ameliorating disorders associated with obesity.
Clin Ther 1996; 18: 1006-1036
26. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL,
Anis AH: The incidence of co-morbidities related to obesity and
overweight: A systematic review and meta-analysis. BMC Public
Health 2009; 9: 88

Thank you for copying data from http://www.arastirmax.com